Senior Scientific Awarded Chinese Patent for Nanoparticle-Based Early Cancer Detection Technology Platform

Senior Scientific, LLC, a unit of Manhattan Scientifics and a developer of nanobiotechnology for the early detection and localization of cancer and other human diseases, today announced that the Company has recently been granted a patent by the Chinese Patent Office, Patent No. CN102695473 A, covering the "Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof."

This patent is an additional patent granted for its MRX™ cancer detection technology that has been granted and issued in by the U.S. Patent office under U.S. Patent No. US 9,095,270 B2.

Bob Proulx, COO and President of Senior Scientific said, “This patent significantly strengthens our IP portfolio for our core MRX technology. With our proprietary cancer detection technology now protected in both the U.S. and China, the two largest markets by population, we now have leverage to pursue a global commercialization and licensing strategy.”